HB6321 would amend title XVIII of the Social Security Act to require Medicare coverage of lung cancer biomarker testing and to define what constitutes such testing. It adds a definition of lung cancer biomarker testing and states that tests furnished on or after January 1, 2027 are eligible for coverage.
The bill also amends Medicare payment rules to pay 100 percent of the reasonable charges for this testing, aligning reimbursement with actual costs to providers. The overall effect is to guarantee access to biomarker testing for eligible patients within the Medicare program, with a concrete payment floor that reduces patient cost concerns.
At a Glance
What It Does
It defines lung cancer biomarker testing and adds it to Medicare's covered services (Section 1861). It also amends payment rules to ensure 100% of reasonable charges are paid for such testing (Section 1833).
Who It Affects
Medicare beneficiaries diagnosed with lung cancer, clinicians ordering tests, and laboratories performing biomarker analyses.
Why It Matters
It expands access to precision diagnostics, clarifies coverage, and creates a predictable payment framework that could influence clinical decision-making and testing utilization.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill amends the Social Security Act to require Medicare coverage of biomarker testing for people diagnosed with lung cancer. It defines what counts as lung cancer biomarker testing—tests that identify one or more biomarkers (genes, proteins, or other molecules) from a patient’s tissue, blood, or bodily fluids and that are furnished on or after January 1, 2027.
In addition to defining testing, the bill changes how Medicare pays for it, directing payment to be 100% of the reasonable charges for the testing. These changes are intended to remove cost barriers for patients and to ensure providers are reimbursed at a level that reflects the diagnostic work involved.
The changes are enacted by updating sections of the Social Security Act related to coverage and payment, without specifying implementation details beyond the defined effective date. The bill does not address broader payer implications beyond Medicare.
This is a policy proposal intended to advance access to targeted diagnostic testing for lung cancer patients within the Medicare program, subject to legislative process and potential administrative rulemaking after enactment.
The Five Things You Need to Know
The bill adds lung cancer biomarker testing to Medicare coverage.
Lung cancer biomarker testing is defined as biomarker analyses from tissue, blood, or bodily fluids.
Medicare must pay 100% of the reasonable charges for these tests.
Tests furnished on or after January 1, 2027 are covered under the act.
The changes modify Sections 1861 and 1833 of the Social Security Act.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Section 1 provides the act’s short title as the Lung Cancer Medicare Access to Precise Testing Act. This establishes the formal naming for referencing the statute in policy discussions and implementation."
Coverage expansion for lung cancer biomarker testing
Section 2(a) expands Medicare coverage by adding lung cancer biomarker testing to the list of services covered under 1861(s)(2). This creates a statutory basis for payment and reproves the scope of tests included under the program—specifically, tests used to identify one or more biomarkers in lung cancer patients.
Definition and scope of testing
Section 2(b) adds a new subsection (nnn) to define lung cancer biomarker testing. It clarifies that these tests are those furnished on or after January 1, 2027 and identify biomarkers (genes, proteins, or other molecules) through analysis of tissue, blood, or bodily fluids.
Payment terms for biomarker testing
Section 2(c) amends section 1833(a)(1) to require payment of 100 percent of the reasonable charges for lung cancer biomarker testing (as defined in the new subsection). This creates a payment floor intended to cover the full cost of testing and reduce patient out-of-pocket concerns.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries diagnosed with lung cancer who will gain access to biomarker testing without coverage gaps.
- Clinicians who order these tests will have clearer coverage and streamlined reimbursement.
- Biomarker testing laboratories and diagnostic developers may see increased demand for these assays.
- Hospitals and cancer centers that perform lung cancer biomarker testing may face strengthened demand and revenue stability.
Who Bears the Cost
- Medicare program and its funding sources will bear higher expenditures from expanded coverage and 100% payment of reasonable charges.
- CMS and provider networks may incur administrative costs to implement the new coverage and payment rules.
- Potential shifts in utilization patterns could impact overall Medicare spending on diagnostics if testing increases.
Key Issues
The Core Tension
Balancing the clinical value and patient access provided by universal biomarker testing coverage against the potential for increased Medicare costs and utilization, all while operationalizing a new definition and payment framework in a real-world health care system.
The bill creates a policy shift toward broader access to precision diagnostics for a major disease area. While improving patient access and provider reimbursement clarity, it raises questions about overall Medicare spending, the administrative burden of implementing the new biomarker testing coverage, and how “reasonable charges” will be defined and audited in practice.
The definition of biomarkers could influence which tests are eligible, and the January 1, 2027 effective date gives CMS time to operationalize coding, coverage determinations, and payer communications. The proposal does not address cost control, private payer dynamics, or potential demand management strategies that may accompany broader diagnostic access.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.